Seagen reports second quarter 2022 financial results

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen) reported financial results today for the second quarter ended june 30, 2022. the company also highlighted padcev® (enfortumab vedotin-ejfv), tukysa® (tucatinib), adcetris® (brentuximab vedotin) and tivdak® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its deep and diverse oncology pipeline. “seagen once again delivered strong commercial performance with record quarterly net product sales
SGEN Ratings Summary
SGEN Quant Ranking